对于科尔萨科夫综合征的多尼佩西尔
Marisa Fallone1, Mauran Sivananthan, Melvin Joseph
1Department of Behavioral Health, Henry Ford Health System, Detroit, MI.
阿尔茨海默病的药物多尼佩齐尔 (donepezil) 可能改善科尔萨科夫综合征 (Korsakoff syndrome) 的症状,这是一种由胺缺乏引起的记忆障碍. 这项案例研究表明,科萨科夫综合征患者对认知和影响有潜在的益处.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
背景情况:
- 科尔萨科夫综合征是一种严重的神经认知障碍,由胺缺乏引起.
- 它的特点是记忆障碍和迷信.
- 沃尼克脑病变在科尔萨科夫综合征之前发生,并且是可逆的,但科尔萨科夫综合征的治疗选择有限.
研究的目的:
- 为了研究多尼佩西尔在患有科尔萨科夫综合征的患者身上带来的潜在益处.
- 为了探索Korsakoff综合征的非标签治疗选择.
主要方法:
- 基于临床记录和患者直接观察的案例研究.
- 对患者对多尼佩西尔治疗反应的回顾性分析.
主要成果:
- 患有科尔萨科夫综合征的患者在开始服用donepezil后,表现出认知,动机和情感的改善.
- 在这种情况下,多尼佩西尔耐受性很好.
结论:
- 在标签之外使用多尼佩西尔可能有助于控制科尔萨科夫综合征的症状.
- 需要进行更大规模的研究来证实多尼佩西尔对科尔萨科夫综合征的安全性和有效性.
更多相关视频
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
10:46Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
相关概念视频
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Drug Dosing: Geriatric Patients
